PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors represent a breakthrough in cancer therapy, utilizing synthetic lethality.
• Approved for BRCA-mutated cancers, PARP inhibitors also show efficacy in patients with homologous recombination (HR) deficiency.
• Despite therapeutic success, acquired resistance limits long-term patient benefit, affecting 40-70% of individuals.

Purpose of the Study:

• To elucidate the mechanisms underlying PARP inhibitor resistance.
• To investigate strategies for overcoming acquired resistance to PARP inhibitors.
• To evaluate the correlation between gene expression patterns and patient survival in the context of PARP inhibitor resistance.

Main Methods:

• Review of PARP inhibitor mechanisms of action and resistance pathways.
• Analysis of gene expression patterns associated with homologous recombination (HR) restoration.
• Exploration of novel therapeutic approaches, including PARP protein degradation via modified inhibitors.

Main Results:

• Identified critical gene expression patterns linked to HR restoration, influencing PARP inhibitor resistance.
• Demonstrated a correlation between specific gene expression profiles and cancer patient survival probabilities.
• Proposed innovative chemical modifications of PARP inhibitors to induce protein degradation.

Conclusions:

• Understanding resistance mechanisms is crucial for optimizing PARP inhibitor therapy.
• Targeting HR restoration pathways and developing PARP-degrading agents are promising strategies.
• These advancements hold potential to enhance PARP inhibitor efficacy and broaden their clinical applications.